Teva Pharmaceutical Industries (TEVA) Study Update summary

Extraordinary overall survival and study results

• Phase IIa trial of Atebimetinib plus chemo in first-line pancreatic cancer showed 94% overall survival at six months and 86% at nine months, nearly double the standard of care benchmarks.

• Results are robust across multiple endpoints: progression-free survival (PFS) at 9.6 months, 70% PFS at six months, 53% at nine months, and strong separation from all standard of care regimens.

• Confirmed overall response rate was 39% and disease control rate 81%, both superior to benchmarks; results held true even in older patients and those with liver metastases.

• Tolerability profile was favorable, with grade III adverse events mainly related to chemotherapy, and Atebimetinib did not add significant toxicity.

• Study population was older (median age 69), yet outcomes matched or exceeded those in younger populations from prior pivotal studies.

Study design, next steps, and strategic outlook

• A global, randomized, pivotal Phase III trial is planned with overall survival as the primary endpoint, aiming to start by year-end and dose first patient by mid-next year.

• Funding secured through a $175M offering and $25M private placement, with strategic investment from Sanofi, providing runway into 2029.

• Additional Phase II studies in lung cancer are planned, including combinations with GENERON's anti-PD-1 and Eli Lilly's KRAS G12C inhibitor.

• Atebimetinib's broad applicability is highlighted by its potential as a backbone for multiple cancer types, with exclusivity expected into at least 2042.

• The company is positioned for value creation with a robust pipeline and strong financial backing.

Q&A insights and monotherapy data

• About half of patients who progress on Atebimetinib plus chemo receive further chemotherapy, while the rest do not; only one received a targeted therapy.

• Atebimetinib is expected to benefit a broad patient population, without need for genetic testing, enabling rapid treatment initiation.

• Monotherapy data showed durable tumor shrinkage and improved quality of life in a third-line pancreatic cancer patient, supporting Atebimetinib's efficacy.

• The study demonstrated lower censoring rates than typical, further supporting data robustness.

• No other company has reported comparable overall survival data in first-line pancreatic cancer.